16 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
1995900	4	Romazarit: a potential disease-modifying antirheumatic drug.	Roche Products
2491889	1	Antiinflammatory 2,6-di-tert-butyl-4-(2-arylethenyl)phenols.	Boehringer Ingelheim Pharmaceuticals
3104589	2	Benzimidazole derivatives with atypical antiinflammatory activity.	TBA
16220969	219	Designed multiple ligands. An emerging drug discovery paradigm.	Organon Laboratories
1635053	47	5-lipoxygenase: properties, pharmacology, and the quinolinyl(bridged)aryl class of inhibitors.	Wyeth-Ayerst Research
3918169	24	Imidazo[1,5-a]pyridines: a new class of thromboxane A2 synthetase inhibitors.	TBA
	21	1-Phenyl-[2H]-tetrahydropyridazin-3-one, A-53612, a selective orally active 5-lipoxygenase inhibitor	TBA
32142276	2	Distribution of Bibenzyls, Prenyl Bibenzyls, Bis-bibenzyls, and Terpenoids in the Liverwort Genus	Tokushima Bunri University
8254620	62	3,4-Dihydroxychalcones as potent 5-lipoxygenase and cyclooxygenase inhibitors.	Tokushima Bunri University
8246226	89	Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.	Ciba-Geigy
8648609	15	Design, synthesis, and biochemical evaluation of N-substituted maleimides as inhibitors of prostaglandin endoperoxide synthases.	Vanderbilt University School of Medicine
3669017	8	Phenylephrine derivatives as leukotriene D4 antagonists.	Wyeth Laboratories
3346867	6	Acetohydroxamic acids as potent, selective, orally active 5-lipoxygenase inhibitors.	Wellcome Research Laboratories
29031075	42	Discovery of new indomethacin-based analogs with potentially selective cyclooxygenase-2 inhibition and observed diminishing to PGE2 activities.	Damanhour University
2113949	126	Effect of structure on potency and selectivity in 2,6-disubstituted 4-(2-arylethenyl)phenol lipoxygenase inhibitors.	Boehringer Ingelheim Pharmaceuticals